US Stock MarketDetailed Quotes
APYX Apyx Medical
- 1.470
- +0.020+1.38%
Trading Apr 29 10:13 ET
50.93MMarket Cap-2722P/E (TTM)
1.500High1.460Low8.14KVolume1.500Open1.450Pre Close12.10KTurnover0.03%Turnover RatioLossP/E (Static)34.64MShares7.97052wk High1.91P/B36.72MFloat Cap1.21052wk Low--Dividend TTM24.98MShs Float17.500Historical High--Div YieldTTM2.77%Amplitude1.210Historical Low1.487Avg Price1Lot Size
Apyx Medical Key Stats
Quarterly+Annual
YOY
| (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | (Q2)Jun 30, 2022 | (Q1)Mar 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 74.12%-5.25M | 51.17%-2.21M | 168.96%3.7M | 17.37%-4.85M | 58.37%-1.88M | -94.09%-20.28M | -2,216.82%-4.53M | -48.68%-5.36M | -17.30%-5.87M | -120.18%-4.52M |
| Net income from continuing operations | 19.02%-18.85M | -58.68%-9.62M | 19.33%-4.68M | 81.30%-1.02M | 40.82%-3.53M | -53.14%-23.28M | -201.74%-6.07M | -36.87%-5.8M | -34.53%-5.45M | -21.67%-5.97M |
| Operating gains losses | 642.67%557K | 321,400.00%3.21M | 24.14%36K | ---- | ---- | 56.25%75K | -200.00%-1K | --29K | --21K | --26K |
| Depreciation and amortization | -22.25%692K | -24.75%152K | -13.89%186K | -38.87%151K | -9.78%203K | -1.44%890K | -11.79%202K | -7.69%216K | 15.96%247K | -0.88%225K |
| Other non cash items | --632K | --222K | --179K | --164K | --67K | ---- | ---- | ---- | ---- | ---- |
| Change In working capital | 206.25%5.54M | 637.71%2.25M | 524.14%6.45M | -27.33%-3.31M | 123.08%156K | -183.07%-5.22M | -346.47%-419K | -79.03%-1.52M | -0.46%-2.6M | -147.41%-676K |
| -Change in receivables | 97.07%3.97M | -1.99%-1.38M | 517.37%7M | -229.36%-2.28M | 32.63%630K | 141.21%2.02M | 21.27%-1.36M | 145.14%1.13M | 231.81%1.76M | -30.15%475K |
| -Change in inventory | 126.20%1.46M | 917.31%1.06M | 94.65%-133K | 87.75%-345K | 336.93%879K | -94.75%-5.57M | 111.86%104K | -216.96%-2.49M | -240.92%-2.82M | 0.27%-371K |
| -Change in prepaid assets | 64.05%-188K | 25,600.00%510K | -2,389.29%-641K | 23.62%-915K | 32.20%858K | -138.60%-523K | -100.15%-2K | -97.54%28K | 18.61%-1.2M | 108.01%649K |
| -Change in payables and accrued expense | 126.38%301K | 147.84%2.07M | 211.68%220K | 164.47%225K | -54.72%-2.21M | -125.08%-1.14M | -40.00%834K | -115.04%-197K | -133.43%-349K | -277.30%-1.43M |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 74.12%-5.25M | 51.17%-2.21M | 168.96%3.7M | 17.37%-4.85M | 58.37%-1.88M | -94.09%-20.28M | -2,216.82%-4.53M | -48.68%-5.36M | -17.30%-5.87M | -120.18%-4.52M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 766.73%6.73M | 34.51%-93K | 7.45%-174K | 1,873.32%7.11M | 60.57%-110K | -39.70%-1.01M | 57.23%-142K | -10.59%-188K | -1,282.76%-401K | -45.31%-279K |
| Net PPE purchase and sale | 766.73%6.73M | 34.51%-93K | 7.45%-174K | 1,873.32%7.11M | 60.57%-110K | -39.70%-1.01M | 57.23%-142K | -10.59%-188K | -1,282.76%-401K | -45.31%-279K |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 766.73%6.73M | 34.51%-93K | 7.45%-174K | 1,873.32%7.11M | 60.57%-110K | -39.70%-1.01M | 57.23%-142K | -10.59%-188K | -1,282.76%-401K | -45.31%-279K |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 14,723.04%32.17M | 238,540.00%23.84M | 29.13%164K | 2,200.00%46K | 8,177.55%8.11M | 804.17%217K | 74.36%-10K | 484.85%127K | -98.73%2K | 260.66%98K |
| Net issuance payments of debt | 23,775.00%35.04M | 257,920.00%25.78M | 56.67%-13K | 81.48%-10K | 17,285.19%9.28M | 37.82%-148K | 82.46%-10K | 50.82%-30K | -42.11%-54K | 34.15%-54K |
| Proceeds from stock option exercised by employees | -76.44%86K | ---586K | -80.89%30K | 0.00%56K | 285.53%586K | 444.78%365K | --0 | 460.71%157K | --56K | 623.81%152K |
| Net other financing activities | ---2.96M | ---1.35M | --147K | --0 | ---1.75M | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 14,723.04%32.17M | 238,540.00%23.84M | 29.13%164K | 2,200.00%46K | 8,177.55%8.11M | 804.17%217K | 74.36%-10K | 484.85%127K | -98.73%2K | 260.66%98K |
| Net cash flow | ||||||||||
| Beginning cash position | -66.98%10.19M | 49.22%22.13M | -7.90%18.48M | -38.04%16.26M | -66.98%10.19M | -26.35%30.87M | -51.99%14.83M | -42.13%20.06M | -33.65%26.23M | -26.35%30.87M |
| Current changes in cash | 259.69%33.65M | 560.04%21.54M | 167.99%3.69M | 136.76%2.31M | 230.26%6.12M | -89.03%-21.07M | -2,882.17%-4.68M | -42.36%-5.42M | -28.56%-6.27M | -103.86%-4.7M |
| Effect of exchange rate changes | -148.35%-191K | -151.22%-21K | -116.23%-31K | -181.00%-81K | -192.06%-58K | 283.50%395K | -68.22%41K | 430.56%191K | 1,011.11%100K | 188.73%63K |
| End cash Position | 328.30%43.65M | 328.30%43.65M | 49.22%22.13M | -7.90%18.48M | -38.04%16.26M | -66.98%10.19M | -66.98%10.19M | -51.99%14.83M | -42.13%20.06M | -33.65%26.23M |
| Free cash flow | 72.84%-5.78M | 50.66%-2.31M | 163.48%3.52M | 20.17%-5.01M | 58.49%-1.99M | -90.57%-21.29M | -3,859.32%-4.67M | -46.97%-5.55M | -24.59%-6.27M | -113.77%-4.8M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg